Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis

Shi, Yachen; Luan, Di; Song, Ruize; Zhang, Zhijun

doi:10.1016/j.euroneuro.2020.09.633

Cited by 54 publications

(31 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In longitudinal studies MDD patients with higher baseline S100B levels exhibit a better response to antidepressant treatment. An elevated S100B level is detected not only in psychiatric conditions but also in many other neurological disorders such as traumatic brain injury, malignant melanoma, amyotrophic lateral sclerosis, and subarachnoid hemorrhage 17 , 30 .…”

Section: Discussionmentioning

confidence: 99%

Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

Rajewska‐Rager

Dmitrzak‐Węglarz

Kapelski

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Mood disorders have been discussed as being in relation to glial pathology. S100B is a calcium-binding protein, and a marker of glial dysfunctions. Although alterations in the S100B expression may play a role in various central nervous system diseases, there are no studies on the potential role of S100B in mood disorders in adolescents and young adults . In a prospective two-year follow-up study, peripheral levels of S100B were investigated in 79 adolescent/young adult patients (aged 14–24 years), diagnosed with mood disorders and compared with 31 healthy control subjects. A comprehensive clinical interview was conducted which focused on clinical symptoms and diagnosis change. The diagnosis was established and verified at each control visit. Serum S100B concentrations were determined. We detected: lower S100B levels in medicated patients, compared with those who were drug-free, and healthy controls; higher S100B levels in a depressed group with a family history of affective disorder; correlations between age and medication status; sex-dependent differences in S100B levels; and lack a of correlation between the severity of depressive or hypo/manic symptoms. The results of our study indicate that S100B might be a trait-dependent rather than a state-dependent marker. Due to the lack of such studies in the youth population, further research should be performed. A relatively small sample size, a lack of exact age-matched control group, a high drop-out rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

Rajewska‐Rager

Dmitrzak‐Węglarz

Kapelski

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…No medication effect on BDNF levels was observed [ 45 ]. Meta-analyses of BDNF studies in adult patients with MDD [ 46 ] or BD [ 47 ] confirmed a significant reduction in peripheral BDNF levels in mood disorders. In our research on adolescent patients, we did not notice differences in BDNF levels between depressive or hypomanic/manic episodes compared to the healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Elevated Epidermal Growth Factor (EGF) as Candidate Biomarker of Mood Disorders—Longitudinal Study in Adolescent and Young Adult Patients

Skibińska

Kapelski

Dmitrzak‐Węglarz

et al. 2021

JCM

View full text Add to dashboard Cite

Bipolar disorder (BD) is a chronic mental disorder that affects more than 1% of the population worldwide. Over 65% of patients experience early onset of the disease. Most cases of juvenile bipolar disorder begin with a depressed mood episode, and up to 50% of youth initially diagnosed with major depression go onto developing a BD. Our study aimed to find biomarkers of diagnosis conversion in young patients with mood disorders. We performed a two-year follow-up study on 79 adolescent patients diagnosed with MDD or BD, with a detailed clinical assessment at five visits. We monitored diagnosis change from MDD to BD. The control group consisted of 31 healthy youths. According to the neurodevelopmental and neuroimmunological hypotheses of mood disorders, we analyzed serum levels of brain-derived neurotrophic factor (BDNF), proBDNF, epidermal growth factor (EGF), migration inhibitory factor (MIF), stem cell factor (SCF), and correlations with clinical factors. We detected a significant disease-dependent increase in EGF level in MDD and BP patients at baseline exacerbation of depressive or hypomanic/manic episodes as well as in euthymic state compared to healthy controls. No potential biological predictors of disease conversion were found. Replication studies on a larger cohort of patients are needed.

show abstract

“…According to our data, there was no significant correlation between S100B levels and MADRS levels before intervention, suggesting that plasma S100B may not be a state marker for depression severity. Although elevated levels of S100B in MDD patients (Schroeter et al, 2013;Shi et al, 2020) and positive correlations between S100B levels and depression severity (Schroeter et al, 2013) have been reported, also reduced levels have been found in cerebrospinal fluid of depressed subjects (Uher and Bob, 2012). Several reasons may account for this inconsistency.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, S100B has been suggested to serve as a biomarker that predicts behavioral responses to chronic fluoxetine treatment ( Benton et al, 2012 ). In humans, peripheral levels of S100B have shown to be elevated in MDD patients ( Arolt et al, 2003 ; Schroeter et al, 2013 ; Shi et al, 2020 ) and associated with depression severity ( Uher and Bob, 2012 ; Schroeter et al, 2013 ). Moreover, clinical reports show a decrease in plasma S100B levels after antidepressant treatment ( Arolt et al, 2003 ; Schroeter et al, 2013 ) and a predictive role of S100B levels for response to treatment with venlafaxine, imipramine, and other antidepressant treatments ( Arolt et al, 2003 ; Ambrée et al, 2015 ; Shi et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Plasma Levels of Brain-Derived Neurotrophic Factor and S100B in Relation to Antidepressant Response to Ketamine

et al. 2021

View full text Add to dashboard Cite

BackgroundEvidence demonstrates that brain-derived neurotrophic factor (BDNF) and S100 calcium-binding protein B (S100B) have a pivotal role in the pathogenesis of major depressive disorder (MDD) and they are proposed as predictors of antidepressant response. Ketamine produces rapid antidepressant effects in MDD and pre-clinical studies suggest the necessity of increased BDNF levels for the antidepressant action of ketamine. However, studies observing the change of blood BDNF levels after ketamine intervention are inconsistent and studies about the role of plasma S100B in ketamine administration in MDD patients are lacking.MethodWe evaluated mature BDNF (mBDNF), S100B levels in plasma and their associations with depression severity in 30 Selective Serotonin Reuptake Inhibitor (SSRI)-resistant MDD patients enrolled in a randomized controlled trial of ketamine compared (n = 20) to a placebo (n = 10) control (saline). Severity of depression was assessed using the Montgomery–Åsberg Depression Rating Scale (MADRS).ResultsPlasma mBDNF and S100B were not significantly changed after 1–2 days of single ketamine compared to placebo. Plasma mBDNF and S100B levels did not significantly differ in responders compared to non-responders of ketamine treatment. The change of plasma mBDNF levels was positively correlated with the improvement of MADRS score after 1–2 weeks of open-label ketamine treatment (rho = 0.495, p = 0.031), though this change did not survive correction for multiple comparisons.ConclusionThese findings do not support the hypothesis that ketamine treatment increases BDNF plasma levels in MDD patients. No effect of ketamine treatment on S100B plasma levels was seen.

show abstract

Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis

Cited by 54 publications

References 43 publications

Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

Elevated Epidermal Growth Factor (EGF) as Candidate Biomarker of Mood Disorders—Longitudinal Study in Adolescent and Young Adult Patients

Plasma Levels of Brain-Derived Neurotrophic Factor and S100B in Relation to Antidepressant Response to Ketamine

Contact Info

Product

Resources

About